External Publications by OHE Authors

Research and commentary by OHE team members appear regularly in external publications.


Cole, A., Shah, K., Mulhern, B., Feng, Y. and Devlin, N., 2018. Valuing EQ-5D-5L health states ‘in context’ using a discrete choice experiment. European Journal of Health Economics, 19(4), pp.595-605. DOI: https://doi.org/10.1007/s10198-017-0905-7.   

Cubí-Mollá, P.Shah, K.K. and Burström, K., 2018. Experience-Based Values: A Framework for Classifying Different Types of Experience in Health Valuation Research. The Patient - Patient-Centered Outcomes Research, DOI: https://doi.org/10.1007/s40271-017-0292-2.

Danzon, P., Drummond, M., Towse, A. and Pauly, M., 2018. Objectives, Budgets, Thresholds, and Opportunity Costs—A Health Economics Approach: An ISPOR Special Task Force Report. Value in Health, 21(2), pp.140-145.

Devlin, N., Brazier, J., Pickard, S.A. and Stolk, E., 2018. 3L, 5L, What the L? A NICE Conundrum. PharmacoEconomics, DOI: https://doi.org/10.1007/s40273-018-0622-9.  

Devlin, N., Shah, K., Feng, Y., Mulhern, B. and van Hout, B., 2018. Valuing Health-related Quality of Life: An EQ-5D-5L Value Set for England. Health Economics, (27), pp.23-28.

Feng, Y., Devlin, N., Shah, K., Mulhern, B. and van Hout, B., 2018. New methods for Modelling EQ-5D-5L Value Sets: An Application to English Data. Health Economics, 27, pp.7-22.

Garrison, L.P., Neumann, P.J., Wilkie, R.J., Basu, A., Danzon, P.M., Doshi, J.A., Drummond, M.F., Lakdawalla, D.N., Pauly, M.V., Phelps, C.E., Towse, A. and Weinstein, M.C., 2018. A Health Economics Approach to US Value Assessment Frameworks—Summary and Recommendations of the ISPOR Special Task Force Report [7]. Value in Health, 21(2), pp.161-165. DOI: https://doi.org/10.1016/j.jval.2017.12.009

Hoque, D.E., Ruseckaite, R., Lorgelly, P., McNeil, J.J. and Evans, S.M., 2018. Cross-Sectional Study of Characteristics of Clinical Registries in Australia: A Resource for Clinicians and Policy Makers. International Journal for Quality in Health Care (Forthcoming. Accepted 27th January 2018).

Karlsberg-Schaffer, S., Messner, D., Mestre-Ferrandiz, J., Tambor, E. and Towse, A., 2018. Paying for Cures: Perspectives on Solutions to the “Affordability Issue”. Value in Health, 21(3), pp.76-279. DOI: https://doi.org/10.1016/j.jval.2017.12.013

Lorgelly, P.K., 2018. The Impact of Brexit on Pharmaceuticals and HTA. PharmacoEconomics, DOI: https://doi.org/10.1007/s41669-018-0072-5.

Lorgelly, P.K. and Neri, M., 2018. Survivorship Burden for Individuals, Households and Society: Estimates and Methodology. Journal of Cancer PolicyDOI: https://doi.org/10.1016/j.jcpo.2018.02.005.

Mott, D.J., 2018. Incorporating Quantitative Patient Preference Data into Healthcare Decision Making Processes: Is HTA Falling Behind? The Patient, DOI: https://doi.org/10.1007/s40271-018-0305-9

Mulhern, B., Feng, Y., Shah, K., Janssen, M.F., Herdman, M., van Hout, B. and Devlin, N., 2018. Comparing the UK EQ-5D-3L and English EQ-5D-5L Value Sets. Pharmacoeconomics, DOI: https://doi.org/10.1007/s40273-018-0628-3

Mulhern, B., Norman, R., Shah, K., Bansback, N., Longworth, L. and Viney, R., 2018. How Should DCE with Duration Choice Sets be Presented for the Valuation of Health States? Medical Decision Making, 38(3), pp.306-318, DOI: http://doi.org/10.1177/0272989X17738754.

Phelps, C.E., Lakdawalla, D.N., Basu, A., Drummond, M.F., Towse, A. and Danzon, P.M. 2018, Approaches to Aggregation and Decision Making—A Health Economics Approach: An ISPOR Special Task Force Report [5] Value in Health, 21(2), pp.146-154. DOI: https://doi.org/10.1016/j.jval.2017.12.010.

Russell, D., Atkin, L., Betts, A., Dowsett, C., Fatoye, F., Gardner, S., Green, J., Manu, C., McKenzie, T., Meally, H., Mitchell, L., Mullings, J., Odeyimi, I., Sharpe, A., Yeowell, G. and Devlin, N., 2018. Using a modified Delphi methodology to gain consensus on the use of dressings in chronic wounds management. Journal of Wound Care, 27(3), pp.156-165. DOI: https://doi.org/10.12968/jowc.2018.27.3.156.

Shah, K.K., Tsuchiya, A. and Wailoo, A.J., 2018. Valuing Health at the End-of-Life: A Review of Stated Preference Studies in the Social Sciences Literature. Social Science & Medicine, 204, pp.39-50, DOI: https://doi.org/10.1016/j.socscimed.2018.03.010.

Towse, A. and Mauskopf. 2018, Affordability of New Technologies: The Next Frontier, Value in Health. DOI: https://doi.org/10.1016/j.jval.2018.01.011.

Wong, E.L., Shah, K., Cheung, A.W.L., Wong, A.Y.K., Visser, M. and Stolk, E., 2018. Evaluation of Split Version and Feedback Module on the Improvement of Time Trade-Off Data. Value in Health, DOI: https://doi.org/10.1016/j.jval.2017.10.013.


Abimanyi-Ochom, J., Lorgelly, P.K., Hollingsworth, B., Inder, B., 2017, Invisible work:  Child work in households with a person living with HIV/AIDS in Central Uganda, SAHARA-J: Journal of Social Aspects of HIV/AIDS, 14(1), 93-109.

Bogosian, A., Hurt, C.S., Vasconcelos, E Sa D, Hindle, J.V., McCracken, L. and Cubí-Mollá, P., 2017. Distant delivery of a mindfulness-based intervention for people with Parkinson's disease: the study protocol of a randomised pilot trial. Pilot Feasibility Studies, 3(4).

Clarke, P., Delziel, K., Tew, M., Lorgelly, P. and Stevens, A., 2017.  Prostheses Benefit Setting Framework - Comparative analysis of benefit setting models. University of Melbourne.

Cowles, E., Marsden, G., Cole, A. and Devlin, N., 2017. A review of NICE methods and processes across health technology assessment programmes: Why the differences and what is the impact? Applied Health Economics and Health Policy. doi:10.1007/s40258-017-0309-y.

Cubí-Mollá, P., Jofre-Bonet, M. and Serra-Sastre, V., 2017. Adaptation to health states: Sick yet better off? Health Economics, DOI: 10.1002/hec.3509.

Devlin, N.J. and Brooks, R., 2017. EQ-5D and the EuroQol Group: Past, Present and Future. Applied Health Economics and Health Policy, 15(2), pp.127-137.

Devlin, N., Lorgelly, P., 2017. QALYs as a measure of value in cancer. Journal of Cancer Policy, 11, pp.19-25.

Doble, B., John, T., Thomas, D., Fellowes, A., Fox, S. and Lorgelly, P., 2017. Cost-effectiveness of precision medicine in the fourth-line treatment of metastatic lung adenocarcinoma: an early decision analytic model of multiplex targeted sequencing. Lung Cancer, 107, pp.22–35.

Elbarazi, I., Devlin, N.J., Katsaiti, M.S., Papadimitropoulos, E.A., Shah, K.K. and Blair, I., 2017. The effect of religion on the perception of health states among adults in the United Arab Emirates: a qualitative study. BMJ Open, 7, e016969.

Feng, Y., Herdman, M., van Nooten, F., Cleeland, C., Parkin, D., Ikeda, S., Igarashi, A. and Devlin, N., 2017. An exploration of differences between Japan and two European countries in the self-reporting and valuation of pain and discomfort on the EQ-5D. Quality of Life Research. doi:10.1007/s11136-017-1541-5.
Feng, Y., Watt, T., Charlesworth, A., Marsden, G., Roberts, A., Sussex, J., 2017. What Determines the Health Care Expenditure of High Income Countries? A Dynamic Estimation. Applied Economics and Finance, 4(6), pp.1-16.
Garau, M. and Devlin, N. (2017). Using MCDA as a decision aid in Health Technology Appraisal for coverage decisions: opportunities, challenges and unresolved questions. In “Multi-Criteria Decision Analysis to Support Healthcare Decisions” Marsh, K., Goetghebeur, M., Thokala, P., Baltussen, R. (Eds.). Springer book. http://www.springer.com/gb/book/9783319475387.
Garau, M., Hampson, G., Devlin, N., Amedeo, N., Amedeo Mazzanti, N., Profico, A., 2017. Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL). PharmacoEconomics (open). DOI: doi:10.1007/s41669-017-0048-x.
Garrison, L., Kamal-Bahl, S. and Towse, A., 2017. Toward a Broader Concept of Value: Identifying and Defining Elements for an Expanded Cost-Effectiveness Analysis. Value in Health, 20(2), pp.213-216.
Hakimi, Z., Herdman, M., Pavesi, M., Devlin, N., Nazir, J., Hoyle, C. and Odeyemi, I.A., 2017. Using EQ-5D-3L and OAB-5D to assess changes in the health-related quality of life of men with lower urinary tract symptoms associated with benign prostatic hyperplasia. Quality of Life Research, 26(5), pp.1187-1195.
Hampson, G., Henshall, C., and Towse, A.,  2017, Assessing value, budget impact and affordability in Asia. International Journal of Technology Assessment in Health Care, 1-8. doi:10.1017/S0266462317000496.
Hampson, G., Towse, A., Pearson, S., Dreitlein, W., Henshall, C. 2017. Gene therapy: evidence, value and affordability in the US health care system. J Comp Eff Res. Nov 16. doi: 10.2217/cer-2017-0068.
Herdman, M., Nazir, J., Hakimi, J., Siddiqui, E., Huang, M., Pavesi, M., MacDiamid, S., Drake, M.J., and Devlin, N. 2017, Assessing Preference-Based Outcome Measures for Overactive Bladder: An Evaluation of Patient-Reported Outcome Data from the BESIDE Clinical Trial. Patient, 10 (6). 
Herdman, M., Pavesi, M., Hakimi, Z., Nazir, J. and Devlin N., 2017. Do Conclusions on the Efficacy of Treatment for Overactive Bladder Depend on the Outcome Measure Used? An Evaluation of Patient-reported Outcome Data from the BESIDE Clinical Trial. The Patient (forthcoming; accepted article). 
Hernandez-Villafuerte, K., Sussex, J., Robin, E., Guthrie, S. and Wooding, S., 2017. Economies of scale and scope in publicly funded biomedical and health research: evidence from the literature. Health Research Policy and Systems, 15(3).
Hoque, D.M.E., Sampurno, F., Ruseckaite, R., Lorgelly, P. and Evans, S.M., 2017. Study protocol of an equivalence randomized controlled trial to evaluate the effectiveness of three different approaches to collecting Patient Reported Outcome Measures (PROMs) data using the Prostate Cancer Outcomes Registry-Victoria (PCOR-VIC). BMC Health Services Research, 17(1), 75.
Knott, R., Black, N., Lorgelly, P. and Hollingsworth, B., 2017, Differential item functioning in quality of life measurement: An analysis using anchoring vignettes, Social Science and Medicine, 190, 247-255.
Knott, R.J., Black, N., Hollingsworth, B. and Lorgelly, P.K., 2017. Response‐Scale Heterogeneity in the EQ‐5D. Health Economics, 26(3), pp.387-394
Knott, R.J., Black, N., Hollingsworth, B. and Lorgelly, P.K., 2017. Response to comment by Robone: Practical advice for the implementation of anchoring vignettes. Health Economics, 26(3), pp.398-400.
Lichten, C.A., Marsden, G., Pollitt, A., Kiparoglou, V., Channon, K.M., and Sussex, J., 2017. Does a biomedical research centre affect patient care in local hospitals? Health Research Policy and Systems, 15(1). 
Lorgelly, P.K., Doble, B., Rowen, D. and Brazier, J., 2017.  Condition-specific or generic preference-based measures in oncology? A comparison of the EORTC-8D and the EQ-5D-3L. Quality of Life Research, 26(5), pp.1163-1176.
Mulhern, B., Norman, R., Lorgelly, P., Lancsar, E., Ratcliffe, J., Brazier, J. and Viney, R., 2017. Is dimension order important when valuing health states using discrete choice experiments including duration? Pharmacoeconomics, 35(4), pp.439–451.
Shah, K.K., 2017. Is willingness to pay higher for cancer prevention and treatment? Journal of Cancer Policy, 11, pp.60-64.
Shah, K.K., Mulhern, B., Longworth, L., Jansen, M.F., 2017. Views of the UK general public on important aspects of health not captured by EQ-5D. The Patient – Patient-Centered Outcomes Research, 10(6), pp.701-709.
Shah, K.K., 2016. Valuing health at the end of life. PhD thesis. Sheffield: University of Sheffield. Available at: http://etheses.whiterose.ac.uk/17579/.
Street, A., Smith, J. and Lorgelly, P., 2017. Is the crisis in the NHS as bad as the Red Cross says it is? The Conversation. 11 Jan 2017. http://theconversation.com/is-the-crisis-in-the-nhs-as-bad-as-the-red-cross-says-it-is-70987
Towse, A. and Garrison, L., 2017. Value assessment in precision cancer medicine. Journal of Cancer Policy, 11, pp.48-53.
Berdud, M., Towse, A. and Kettler, H., 2016.  Fostering incentives for research, development, and delivery of interventions for neglected tropical diseases: lessons from malaria. Oxford Review of Economic Policy, 32(1), pp.64-87. 
Berdud, M., Cabasés, J.M. and Nieto, J., 2016. Incentives and intrinsic motivation in healthcare. Gaceta Sanitaria. 30(6), pp.408-414.
Cole, A., 2016. Managing real world data governance. Pharmaceutical Market Europe. 28th April 2016. Available at: http://www.pmlive.com/pharma_intelligence/managing_real_world_data_governance_1007710
Doble, B. and Lorgelly, P., 2016. Mapping the EORTC QLQ-C30 onto the EQ-5D-3L: assessing the external validity of existing mapping algorithms. Quality of Life Research, 25(4), pp.891-911.
Dodson, S., Klassen, K.M., McDonald, K., Millard, T., Osborne, R.H., Battersby, M.W., Fairley, C.K., Simpson, J.A., Lorgelly, P., Tonkin, A. and Roney, J., 2016. HealthMap: a cluster randomised trial of interactive health plans and self-management support to prevent coronary heart disease in people with HIV. BMC Infectious Diseases, 16(114).
Fischer, A.J. and Ghelardi, G., 2016. The precautionary principle, evidence-based medicine and decision theory in public health evaluation. Frontiers in Public Health, 4(107).
Fisher, J., Rowe, H., Wynter, K., Tran, T., Lorgelly, P., Amir, L., Proimos, J., Ranasinha, S., Hiscock, H., Bayer, J. and Cann, W., 2016. A gender-informed, psychoeducational program for couples to prevent postnatal common mental disorders among primiparous women: cluster randomised controlled trial. BMJ Open, 6, e009396.
Garau, M., Shah, K.K., Sharma, P. and Towse, A., 2016.  Is the link between health and wealth considered in decision making? Results from a qualitative study. International Journal of Technology Assessment in Health Care, 31(6), pp.449-456.
Garrison, L., Mestre-Ferrandiz, J. and Zamora, B., 2016. The Value of Knowing and Knowing the Value: Improving the Health Technology Assessment of Complementary Diagnostics. EPEMED White Paper. Luxembourg: The European Personalised Medicine Association.
Greco, G., Lorgelly, P. and Yamabhai, I., 2016. Outcomes in economic evaluations of public health interventions in low- and middle-income countries: health, capabilities and subjective wellbeing. Health Economics, 25(Suppl 1), pp.83-94.
Gauthier, S., Albert, M., Fox, N., Goedert, M., Kivipelto, M., Mestre-Ferrandiz, J. and Middleton, L.T., 2016. Why has therapy development for dementia failed in the last two decades? Alzheimer’s & Dementia, 12(1), pp.60–64.
Herdman, M.Cole, A., Hoyle, C. K., Coles, V., Carroll, S. and Devlin, N., 2016. Sources and Characteristics of Utility Weights for Economic Evaluation of Pediatric Vaccines: A Systematic Review. Value in Health, 19, pp.255-266.
Herdman, M., Hoyle, C.K., Coles, V., Carroll, S. and Devlin, N., 2016. Assessing patient reported outcomes in paediatric populations with vaccine-preventable infectious diseases: a systematic review of the literature (the PROCHID Study). Value in Health, 19, pp.109-119. 
Hernandez-Villafuerte, K., Li, R, Hofman, K.J. 2016. Bibliometric Trends of Health Economic Evaluation in Sub-Saharan Africa. Globalization & Health, 12(50).
Karlsberg Schaffer, S., Sussex, J., Hughes, D. and Devlin, N., 2016. Opportunity costs and local health service spending decisions: a qualitative study from Wales. BMC Health Services Research, 16(103).
Li, R., Hernandez-Villafuerte, K., Towse, A., Vlad, I. and Chalkidou, K., 2016.  Mapping priority setting in health in 17 countries across Asia, Latin America, and sub-Saharan Africa. Health Systems & Reform, 2, pp.71-83
Lorgelly, P.K., Doble, B., Knott, R. and Cancer 2015 investigators, 2016. Realising the value of linked data to health economic analyses of cancer care: a case study of Cancer 2015. Pharmacoeconomics, 34(2), pp.139-154.
Marsh, K., IJzerman, M., Thokala, P., Baltussen, R., Boysen, M., Kaló, Z., Lönngren, T., Mussen, F., Peacock, S., Watkins, J. and Devlin, N., 2016. Multiple Criteria Decision Analysis for Health Care Decision Making—Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force. Value in Health, 19(2), pp.125-137.
Mestre-Ferrandiz, J., Towse, A. and Berdud, M., 2016. Biosimilars: How Can Payers Get Long-Term Savings? Pharmacoeconomics, 34, pp.609-616.
Mestre-Ferrandiz, J., Towse, A. and Berdud, M., 2016. Biosimilars: achieving long-term savings and competitive markets. GaBI-Generics and Biosimilars Initiative Journal, 5(3).
Morton, A., Adler, A.I., Bell, D., Briggs, A., Brouwer, W., Claxton, K., Craig, N., Fischer, A., McGregor, P. and Baal, P., 2016. Unrelated Future Costs and Unrelated Future Benefits: Reflections on NICE Guide to the Methods of Technology Appraisal. Health Economics, 25(8), pp.933-938.
Mulhern, B., Shah, K., Janssen, M.F., Longworth, L. and Ibbotson, R., 2016. Valuing health using time trade-off and discrete choice experiment methods: does dimension order impact on health state values? Value in Health, 19, pp.210-217.
Mutowo, M.P., Lorgelly, P.K., Laxy, M., Renzaho, A., Mangwiro, J.C. and Owen, A.J., 2016. The Hospitalization Costs of Diabetes and Hypertension Complications in Zimbabwe: Estimations and Correlations. Journal of Diabetes Research, Article ID 9754230.
Oppe, M., Rand-Hendriksen, K., Shah, K., Ramos-Goñi, J.M., Luo, N., 2016. EuroQol protocols for time trade-off valuation of health outcomes. Pharmacoeconomics, 34, pp.993-1004.
Parkin, D., Devlin, N. and Feng, Y., 2016. What Determines the Shape of an EQ-5D Index Distribution? Medical Decision Making, 36(8), pp.941-951.
Ride, J., Lorgelly, P., Tran, T., Wynter, K., Rowe, H. and Fisher, J., 2016. Preventing postnatal maternal mental health problems using a psychoeducational intervention: the cost-effectiveness of What Were We Thinking. BMJ Open, 6(11), e012086.
Shah, K., Mulhern, B., Longworth, L. and Janssen, M.F., 2016. An empirical study of two alternative comparators for use in time trade-off studies. Value in Health, 19, pp.53-59.
Shah, K.K., 2016. Does society place special value on end of life treatments? In: Round, J., ed. Care at the end of life: An economic perspective. Cham: Springer. pp.155-166.
Sussex, J., Feng, Y., Mestre-Ferrandiz, J., Pistollato, M., Hafner, M., Burridge, P. and Grant, J., 2016. Quantifying the economic impact of government and charity funding of medical research on private research and development funding in the United Kingdom. BMC Medicine, 14(32).
Thokala, P., Devlin, N, Marsh, K., Baltussen, R., Boysen, M., Kalo, Z., Longrenn, T., Mussen, F., Peacock, S., Watkins, J. and IJzerman, M., 2016. Multiple Criteria Decision Analysis for Health Care Decision Making—An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force. Value in Health, 19, pp.1-13.
van Baal, P.H., Hoogendoorn, M. and Fischer, A., 2016. Preventing dementia by promoting physical activity and the long-term impact on health and social care expenditures. Preventive Medicine, 85, pp.78-83.
Wong, S.F., Norman, R., Dunning, T.L., Ashley, D.M., Khasraw, M., Hayes, T.M., Collins, I. and Lorgelly, P.K., 2016. A Discrete Choice Experiment to Examine the Preferences of Patients with Cancer and Their Willingness to Pay for Different Types of Health Care Appointments. Journal of the National Comprehensive Cancer Network, 14(3), pp.311-319.


Calvert, M., Kyte, D., Thwaites, R. and Devlin, N., 2015. Putting patient reported outcomes on the ‘big data roadmap’. Journal of the Royal Society of Medicine, Available at http://jrs.sagepub.com/content/early/2015/01/16/0141076815579896.full [Accessed 08 April 2015].

Claxton, K., Martin, S., Soares, M., Rice, N., Spackman, E., Hinde, S., Devlin, N., Smith, P.C. and Sculpher, M., 2015. Methods for the estimation of the NICE cost effectiveness threshold. Health Technology Assessment, 19(14).
Cubí-Mollá, P., Peña-Longobardo, L.M., Casal, B., Rivera, B. and Oliva, J., 2015. Pérdidas laborales atribuibles a la mortalidad prematura por lesiones de tránsito entre 2002 y 2012. [Labour productivity losses attributable to premature deaths due to traffic injuries between 2002 and 2012]. Gaceta Sanitaria, 29, pp.79-84 
Dakin, H., Devlin, N., Feng, Y., Rice, N., O’Neill, P. and Parkin, D., 2015. The influence of cost-effectiveness and other factors on NICE decisions. Health Economics, 24(10), pp.1256-1271.
Danzon, P.M., Mulcahy, A.W. and Towse, A.K., 2015. Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition, and Procurement. Health Economics, 24(2), pp.238-252.
Devlin, N., Herdman, M., Pavesi, M., Phung, D., Naidoo, S., Beer, T.M., Tombal, B., Loriot, Y., Ivanescu, C., Parli, T., Balk, M. and Holmstrom, S., 2015.  Health-Related Quality Of Life (Hrqol) Benefits Of Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer (Mcrpc): An In-Depth Analysis of EQ-5D Data from the Prevail Trial. Value in Health. 18(7), A475.  Doi: 10.1016/j.jval.2015.09.1270. Epub 2015 Oct 20.
Feng, Y., Devlin, N. and Herdman, M., 2015. Assessing the health of the general population in England: how do the three- and five-level versions of EQ-5D compare? Health and Quality of Life Outcomes, 13:171. Doi: 10.1186/s12955-015-0356-8.
Feng, Y., Ma, A., Farrar, S. and Sutton, M., 2015. The tougher the better: an economic analysis of increased payment thresholds on the performance of general practice. Health Economics, 24(3), pp.353-371.
Feng, Y., Pistollato, M., Charlesworth, A., Devlin, N., Propper, C. and Sussex, J., 2015. Association between market concentration of hospitals and patient health gain following hip replacement surgery. Journal of Health Services Research & Policy, 20(1), pp.11-17.
Girling, A., Lilford, R., Cole, A. and Young, T., 2015.  Headroom approach to device development: Current and future directions. International Journal of Technology Assessment in Health Care, 31(5), pp.331–338.
Hanney, S.R., Castle-Clarke, S., Grant, J., Guthrie, S., Henshall, C., Mestre-Ferrandiz, J., Pistollato, M., Pollitt, A., Sussex, J. and Wooding, S. 2015. How long does biomedical research take? Studying the time taken between biomedical and health research and its translation into products, policy and practice. Health Research Policy and Systems, 13(1), pp.1-18.
Jaczynska, E., Outterson, K. and Mestre-Ferrandiz, J., 2015. Business Model Options for Antibiotics. Learning from Other Industries. London: Chatham House and Big Innovation Centre.
Karlsberg Schaffer, S., 2015. The effect of free personal care for the elderly on informal caregiving. Health Economics, 24(S1), pp.104-117.
Karlsberg Schaffer, S., Sussex, J., Devlin, N. and Walker, A., 2015. Local health care expenditure plans and their opportunity costs. Health Policy, 119(9), pp.1237-1244.
Luo, N., Wang, Y., How, C.H., Tay, E.G., Thumboo, J. and Herdman, M., 2015. Interpretation and use of the 5-level EQ-5D response labels varied with survey language among Asians in Singapore. Journal of Clinical Epidemiology, (Epub ahead of print).
Messner, D.A., Mohr, P. and Towse, A., 2015. Futurescapes: evidence expectations in the USA for comparative effectiveness research for drugs in 2020. Journal of Comparative Effectiveness Research, 4(4), pp.385-400.
Messner, D.A., Towse, A., Mohr, P. and Garau, M., 2015. The future of comparative effectiveness and relative efficacy of drugs: an international perspective. Journal of Comparative Effectiveness Research, 4(4), pp.419-427.
Moloney, R., Mohr, P., Hawe, E., Shah, K., Garau, M. and Towse, A., 2015. Payer perspectives on future acceptability of comparative effectiveness and relative effectiveness research. International Journal of Technology Assessment in Health Care, 31(1-2), pp.90-98.
Papadimitropoulos, M., Elbarazi, I., Blair, I., Katsaiti, M.S., Shah, K.K. and Devlin, N., 2015. An investigation of the feasibility and cultural appropriateness of stated preference methods to generate health state values in the United Arab Emirates. Value in Health Regional Issues, 7C, pp.34-41.
Parkin, D., Morris, S. and Devlin, N., 2015. Economic appraisal in public health care: assessing efficiency and equity. Chapter 6.6 in: Detels, R., Gulliford, M., Abdool Karim, Q. and Tan, C.C., eds. Oxford Textbook of Public Health (6th edition). Oxford University Press.
Puig-Peiro, R., Mason, A., Mestre-Ferrandiz, J., Towse, A., McGrath, C. and Jonsson, B., 2015. Relative effectiveness in breast cancer treatment: A health production approach.  International Journal of Technology Assessment in Health Care, 31, pp.371–379 
Robles, N., Rajmil, L., Rodriguez-Arjona, D., Azuara, M., Codina, F., Raat, H., Ravens-Sieberer, U. and Herdman, M., 2015. Development of the web-based Spanish and Catalan versions of the Euroqol 5D-Y (EQ-5D-Y) and comparison of results with the paper version. Health and Quality of Life Outcomes, 13(1), pp.72-80.
Shah, K.K., Sussex, J. and Hernandez-Villafuerte, K., 2015. Government and charity funding of cancer research: public preferences and choices. Health Research Policy and Systems, 13(28).
Shah, K.K., Tsuchiya, A. and Wailoo, A.J., 2015. Valuing health at the end of life: A stated preference discrete choice experiment. Social Science & Medicine, 124, pp.48-56.
Towse, A., Garau, M., Mohr, M. and Messner, D.A., 2015.  Futurescapes: expectations in Europe for relative effectiveness evidence for drugs in 2020. Journal of Comparative Effectiveness Research, 4(4), pp.401-418.
Towse, A., Jonsson, B., McGrath, C.L., Mason, A., Puig-Peiro. R., Mestre-Ferrandiz, J., Pistollato, M. and Devlin, N., 2015.  Understanding variations in relative effectiveness: A Health Production Approach.  International Journal of Technology Assessment in Health Care, 31(6), pp. 363–370.
Towse, A., Pistollato, M., Mestre-Ferrandiz, J., Khan, Z., Kaura, S. and Garrison, L., 2015. European Union Pharmaceutical Markets: A Case for Differential Pricing? International Journal of the Economics of Business, 22(2), pp.263-275.
Wong, S.F., Matheson, L., Morrissy, K., Pitson, G., Ashley, D.M., Khasraw, M., Lorgelly, P.K. and Henry, M.J., 2015. Retrospective analysis of cancer survival across South‐Western Victoria in Australia. Australian Journal of Rural Health, 24(2), pp.79-84.
Buxton, M., Longworth, L., Raftery, J., Schulpher, M. and Towse, A., 2014. Reforming the Cancer Drug Fund.  British Medical Journal, 349 doi: http://dx.doi.org/10.1136/bmj.g7276 (Published 28 November 2014) Cite this as: BMJ 2014;349:g7276.
Chapman, A.M., Taylor, C.A. and Girling, A.J., 2014. Are the UK Systems of Innovation and Evaluation of Medical Devices Compatible? The Role of NICE's Medical Technologies Evaluation Programme (MTEP). Appl Health Econ Health Policy, 12(4), pp.347-357.
Chawla, A.J., Mytelka, D S., McBride, S. D., Nellesen, D., Elkins, B.R., Ball, D.E., Kalsekar, A., Towse, A. and Garrison, L.P., 2014. Estimating the incremental net health benefit of requirements for cardiovascular risk evaluation for diabetes therapies. Pharmacoepidemiology and Drug Safety, 23(3), pp.268-277.
Cubí-Mollá, P., de Vries, J. and Devlin, N., 2014. A study of the relationship between health and subjective well-being in Parkinson's Disease patients. Value in Health, 17(4), pp.372-379.
Drummond, M. and Towse, A., 2014. Orphan drugs policies: a suitable case for treatment. The European Journal of Health Economics, 15(4), pp.335-340.
Feng, Y., Parkin, D. and Devlin, N.J., 2014. Assessing the performance of the EQ-VAS in the NHS PROMs Programme. Quality of Life Research, 23(3), pp.977-989.
Garrison, L.P. and Towse, A., 2014. Economics of personalized medicine: pricing and reimbursement policies as a potential barrier to development and adoption. In: A. Culyer ed. Encyclopedia of Health Economics. San Diego, CA: Elsevier. pp.484-490.
Hernandez-Villafuerte, K., 2014. El adulto mayor y la universalidad de la salud: Análisis de desigualdad basado en una comparación entre los diferentes grupos de edad. Estudios de Economia Aplicada, [Available in Spanish only.]
Krabbe, P.F.M., Devlin, N.J., Stolk, E.A., Shah, K.K., Oppe, M., van Hout, B., Quik, E.H., Pickard, A.S. and Xie, F., 2014. Multinational Evidence of the Applicability and Robustness of Discrete Choice Modeling for Deriving EQ-5D-5L Health-State Values. Medical Care, 52(11), pp.935-943.
Mulhern, B., Bansback, N., Brazier, J., Buckingham, K., Cairns, J., Devlin, N., Dolan, P., Hole, A.R., Kavetsos, G., Longworth, L., Rowen, D., Tsuchiya, A., 2014. Preparatory study for the revaluation of the EQ-5D tariff: methodology report. Health Technology Assessment, 18(12), pp.vii-191. doi 10.3310/hta18120.
Oppe, M., Devlin, N., van Hout, B., Krabbe, P.F.M. and de Charro, F., 2014. A program of methodological research to arrive at the new international EQ-5D-5L valuation protocol. Value in Health, 17(4), pp.445-453.
Rejón-Parrilla, J.C., Nuijten, M., Redekop, W.K. and Gaultney, J.G., 2014. Economic evaluation of the use of a pharmacogenetic diagnostic test in schizophrenia. Health Policy and Technology, 3(4), pp.314-324.
Shah, K.K., Tsuchiya, A. and Wailoo, A.J., 2014. Valuing health at the end of life: an empirical study of public preferences. European Journal of Health Economics, 15(4), pp.389-399. 
Street, A., Gutacker, N., Bojke, C., Devlin, N. and Daidone, S., 2014. Variations in outcome and costs among NHS providers for common surgical procedures: econometric analysis of routinely collected data. Health Services and Delivery Research, 2(1), pp.1-89.
Towse, A., 2014. Comparative and relative effectiveness: a challenge for health systems, regulators, or the pharmaceutical industry? In: Culyer, A.J. and Kobelt, G. eds. Portrait of a health economist: essays by colleagues and friends of Bengt Jonsson. Lund: Swedish Institute for Health Economics, pp.179-188.
Towse, A., 2014. Value of drugs in practice. In: A. Culyer ed. Encyclopedia of Health Economics. San Diego, CA: Elsevier. pp.432-440.

Appleby, J., Poteliakhoff, E., Shah, K. and Devlin, N., 2013. Using patient-reported outcome measures to estimate cost-effectiveness of hip replacements in English hospitals. Journal of the Royal Society of Medicine, 106(8), pp.323-331.

Augustovski, F., Rey-Ares, L., Irazola, V., Oppe, M. and Devlin, N.J., 2013. Lead versus lag-time trade-off variants: Does it make any difference? European Journal of Health Economics, 14(1Suppl), pp.25-31.

Danzon, P.M., Mulcahy, A.W. and Towse, A.K., 2013. Pharmaceutical pricing in emerging markets: Effects of income, competition and procurement. Health Economics, Epub. doi: 10.1002/hec.3013.

Danzon, P., Towse, A. and Mestre-Ferrandiz, J., 2013. Value-based differential pricing: Efficient prices for drugs in a global context. Health Economics, Epub. doi: 10.1002/hec.3021.

Devlin, N. and Krabbe, P., 2013. The development of new research methods for the valuation of EQ-5D-5L. European Journal of Health Economics, 14(1Suppl), pp.1-3.

Devlin, N., Buckingham, K., Shah, K.K., Tsuchiya, A., Tilling, C., Wilkinson, G. and van Hout, B., 2013. A comparison of alternative variants of the lead and lag time TTO. Health Economics, 22(5), pp.517-532.

Garau, M., Towse, A., Garrison, L., Housman, L. and Ossa, D., 2013. Can and should value-based pricing be applied to molecular diagnostics? Personalized Medicine, 10(1), pp.61-72.

Garrison, L.P., Towse, A.K., Briggs, A., de Pouvourville, G., Grueger, J., Mohr, P.E., Severens, J.L., Siviero, P. and Sleeper, M., 2013. Performance-based risk-sharing - Good practices for design, implementation, and evaluation: Report of the ISPOR Good Practices for Performance-based Risk-sharing Task Force. Value in Health, 16(5), pp.703-719.

Gutacker, N., Bojke, C., Daidone, S., Devlin, N. and Street, A., 2013. Hospital variation in patient-reported health outcomes at the level of EQ-5D dimensions: Evidence from England. Medical Decision Making, 33(6), pp.804-818. 

Luo, N., Li, M., Stolk, E.A. and Devlin, N., 2013. The effects of lead time and visual aids in TTO valuation: A study of the EQ-VT framework. European Journal of Health Economics, 14(1Suppl), pp.15-24.

Mestre-Ferrandiz, J., 2013. Increasing R&D costs for new medicines. C&I Magazine, Comment. 9 April. 44.

Mulhern, B., Longworth, L., Brazier, J., Rowen, D., Bansback, N., Devlin, N. and Tsuchiya, A., 2013. Binary choice health state valuation and mode of administration: Head to head comparison of online and CAPI. Value in Health, 16(1).

Nuttall, D., Parkin, D. and Devlin, N., 2013. Inter-provider comparison of patient-reported outcomes: developing an adjustment to account for differences in case-mix. Health Economics, Early view. doi: 10.1002/hec.299.

O’Neill, P., Mestre-Ferrandiz, J., Puig-Peiro, R. and Sussex, J., 2013. Projecting expenditures on medicines in the UK NHS. PharmacoEconomics, 31(10), pp.933-957. 

Pavesi, M., Devlin, N., Hakimi, Z., Nazir, J., Hoyle, C. and Odeyemi, I., 2013. Understanding the effects on HR-QoL of treatment for overactive bladder: A detailed analysis of EQ-5D clinical trial data for mirabegron. Journal of Medical Economics, 16(7), pp.866-876.

Sadique, Z., Devlin, N., Parkin, D. and Edmunds, J., 2013. The effect of perceived risks on the demand for vaccination: results from a discrete choice experiment. Public Library of Science (PLOS One), 8(2), e54149.

Shah, K.K., Cookson, R., Culyer, A. and Littlejohns, P., 2013. NICE's social value judgements (SVJ) about equity in health and health care. Health Economics, Policy and Law, 8(2), pp.145-165.

Shah, K.K., Lloyd, A., Oppe, M. and Devlin, N.J., 2013. One-to-one versus group setting for conducting computer-assisted TTO studies: Finding from pilot studies in England and the Netherlands. European Journal of Health Economics, 14(1Suppl), pp.66-73. 

Shah, K.K., Mestre-Ferrandiz, J., Towse, A. and Smyth, E.H., 2013. A review of health technology appraisals: Case studies in oncology. International Journal of Technology Assessment in Health Care, FirstView article. 29(1), pp.101-109.

Sussex, J., Rollet, P., Garau, M., Schmitt, C., Kent, A. and Hutchings, A., 2013. A pilot study of multicriteria decision analysis for valuing orphan medicines. Value in Health, 16(8), pp.1163-1169.

Sussex, J., Towse, A. and Devlin, N., 2013. Operationalising value based pricing of medicines: A taxonomy of approaches. PharmacoEconomics, 13(1), pp.1-10.

Towse, A. and Barnsley, P., 2013. Approaches to identifying, measuring, and aggregating elements of value. International Journal of Technology Assessment in Health Care, 29(4), pp.360-364.

Towse, A. and Garrison, L.P., 2013. Economic incentives for evidence generation: promoting an efficient path to personalized medicine. Value in Health, 16(6 Suppl), S39-S43. doi: 10.1016/j.jval.2013.06.003.

Towse, A., Ossa, D., Veenstra, D., Carlson, J. and Garrison, L., 2013. Understanding the economic value of molecular diagnostic tests: Case studies and lessons learned. Journal of Personalized Medicine, 3(4), pp.288-305. doi: 10.339/jpm3040288.

Versteegh, M.M., Attema, A.E., Oppe, M., Devlin, N.J. and Stolk, E.A., 2013. Time to tweak the TTO: Results from a comparison of alternative specifications of the TTO. European Journal of Health Economics, 14(1Suppl), pp.43-51.


Berger, M.L., Dreyer, N., Anderson, F., Towse, A., Sadrakyan, A. and Normand, S-L., 2012. Prospective observational studies to assess comparative effectiveness: The ISPOR Good Research Practices Task Force report. Value in Health, 15, pp.217-230.

Danzon, P.M., Towse, A.K. and Mestre-Ferrandiz, J., 2012. Value-based differential pricing: Efficient prices for drugs in a global context. NBER Working Paper No. 18593. Cambridge, MA: National Bureau of Economic Research.

Drummond, M. and Towse, A., 2012. Is it time to reconsider the role of patient co-payments for pharmaceuticals in Europe? European Journal of Health Economics, 13(1), pp.1-5.

Gutacker, N., Bojke, C., Daidone, S., Devlin, N.J., Parkin D. and Street, A., 2012. Truly inefficient or providing better quality of care? Analysing the relationship between risk-adjusted hospital costs and patients' health outcomes. Health Economics, doi: 10.1002/hec.2871.

Gutacker, N., Bojke, C., Daidone, S., Devlin, N., and Street, A., 2012. Analysing hospital variations in health outcomes at the level of EQ-5D dimensions. CHE research paper. 74. York: Centre for Health Economics, University of York.

Melamed, C., Devlin, N. and Appleby, J., 2012. 'Valuing development': Could approaches to measuring outcomes in health help make development more accountable?  Research reports and studies. London: Overseas Development Institute.

Mestre-Ferrandiz, J., 2012. Opinion: ¿Son útiles las proyecciones del gasto farmacéutico? [Is projecting the medicines bill useful?] ElGlobal.net, 27 July. Available at http://www.elglobal.net/articulo.aspx?idart=657995&idcat=774&tipo=2. [Accessed 27 July 2012].

Morris, S., Devlin, N., Parkin, D. and Spencer, A., 2012. Economic analysis in healthcare, second edition. Chichester, UK: John Wiley & Sons, Ltd. 

Spellberg, B., Sharma, P. and Rex, J.H., 2012. The critical impact of time discounting on economic incentives to overcome the antibiotic market failure. Nature Reviews Drug Discovery, 11(2), pp.168-170.

Shah, K., Praet, C., Devlin, N., Sussex, J., Appleby J. and Parkin, D., 2012. Is the aim of the English health care system to maximize QALYs? Journal of Health Services Research and Policy, 17(3), pp.157-163.

Shah, K., Tsuchiya, A., Risa Hole, A., and Wailoo, A., 2012. Valuing health at the end of life: A stated preference discrete choice experiment. NICE Decision Support Unit report.  Sheffield: Decision Support Unit.

Towse, A., Drummond, M. and Sorensen, C., 2012. Pharmacoeconomics theory and practice. In: Danzon, P. and Nicholson, S. eds. Oxford handbook on the economics of the biopharmaceutical industry. Oxford: Oxford University Press.

Towse, A., Keuffel, E., Kettler, H.E. and Ridley, D.B., 2012. Drugs and vaccines for developing countries. In: Danzon, P. and Nicholson, S. eds. Oxford handbook on the economics of the bopharmaceutical industry. Oxford: Oxfrod University Press

Watson, V., Sussex, J., Ryan, M. and Tetteh, E., 2012. Managing poorly performing clinicians: Health care providers’ willingness to pay for independent help. Health Policy, 104(3), pp.260-271.


Barham, L. and Devlin, N., 2011. Patient reported outcomes in the English NHS: Implications and opportunities for nursing. Nursing Standard, 25(18), pp.42-45.

Danzon, P., Mulcahy, A.W. and Towse, A., 2011. Pharmaceutical pricing in emerging markets: Effects of income, competition and procurement. NBER Working Paper No. 17174. Cambridge, MA: National Bureau of Economic Research.

Danzon, P.M., Towse, A. and Mulcahy, A.W., 2011. Setting cost-effectiveness thresholds as a means to achieve appropriate drug prices in rich and poor countries. Health Affairs, 30(8), pp.1529-1538.

Devlin, N., Tsuchiya, A., Buckingham, K. and Tilling, C., 2011. A uniform time trade off method for states better and worse than dead: Feasibility study of the ‘lead time’ approach. Health Economics, 20(3), pp.348-361.

Garau, M., Shah, K.K., Mason, A., Wang, Q., Towse, A. and Drummond, M., 2011. Using QALYs in cancer: A review of the methodological limitations. PharmacoEconomics, 29(8), pp.673-685.

Gutacker, N., Bojke, C., Daidone, S., Devlin, N., Parkin, D. and Street, A., 2011. Truly inefficient or providing better quality of care? Analysing the relationship between risk-adjusted hospital costs and patients’ health outcomes. CHE Research Paper 68. York: University of York.

Parkin, D. and Devlin, N., 2011. Using health status to measure NHS performance: Casting light in dark places. BMJ Safety and Quality, [Epub ahead of print: doi:10.1136/bmjqs-2011-000362].

Shah, K.K., Cookson, R., Culyer, A. and Littlejohns, P., 2011. NICE’s social value judgments about equity in health and health care. CHE Research Paper 70. York: University of York.

Towse, A. and Sharma, P., 2011. Incentives for R&D for new antimicrobial drugs. International Journal of the Economics of Business, 18(2), pp.331-350.


Devlin, N., 2010. The economics of a 'liberated' NHS. PharmacoEconomics, 28(12), pp.1075-1078.

Devlin, N., Parkin, D. and Browne, J., 2010. Patient-reported outcomes in the NHS: New methods for analysing and reporting EQ-5D data. Health Economics, 19(8), pp.886-905.

Dixon, A., Robertson, R., Appleby, J., Burge, P., Devlin, N. and Magee, H., 2010. Patient choice: How patients choose and how providers respond. London: King's Fund.

O'Neill, P. and Devlin, N., 2010. An analysis of NICE's restricted (or 'optimised') decisions. PharmacoEconomics, 28(11), pp.987-993.

Parkin, D., Rice, N. and Devlin, N., 2010. Statistical analysis of EQ-5D profiles: Does the use of value sets bias inference? Medical Decision Making, 30(5), pp.556-565.

Ravens-Sieberer, U., Wille, N., Badia, X., Bonsel, G., Burstrom, K., Cavrini, G., Devlin, N., Egmar, A.C., Gusi, N., Herdman, M., Jelsma, J., Kind, P., Olivares, P., Scalone, L. and Griener, W., 2010. Feasibility, reliability and validity of the EQ-5D-Y: Results from a multi-national study. Quality of Life Research, 19(6), pp.887-897.

Tilling, C., Devlin, N., Tsuchiya, A., and Buckingham, K., 2010. Protocols for time tradeoff valuations of health states worse than dead: A literature review. Medical Decision Making, 30(5), pp.610-619.

Towse, A., 2010. Value based pricing, research, and development and patient access schemes. Will the United Kingdom get it right or wrong? British Journal of Clinical Pharmacology, 70(3), pp.306-366.

Towse, A. and Danzon, P., 2010. The regulation of the pharmaceutical industry. In: Baldwin, R., Cave M. and Lodge, M. eds. Oxford handbook on regulation. New York: Oxford University Press. pp.548-571.

Towse, A. and Garrison, L.P., 2010. Can’t get no satisfaction? Will pay for performance help? Toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products. PharmacoEconomics, 28(2), pp.93-102.

Wille, N., Badia, X., Bonse, G., Burstrom, K., Cavrin, G., Devlin, N., Egmar, A.C., Greiner, W., Gusi, N., Herdman, M., Jelsma J., Kind, P., Scalone, L. and Ravens-Sieberer, U., 2010. Development of the EQ-5D-Y: A child-friendly version of the EQ-5D. Quality of Life Research, 19(6), pp.875-886


Appleby, J., Devlin, N., Parkin, D., Chalkidou, K. and Buxton, M., 2009. Searching for cost effectiveness thresholds in the NHS. Health Policy, 91(3), pp.239-245.

Buckingham, K. and Devlin, N., 2009. An exploration of the marginal utility of time in health. Social Science & Medicine, 68(2), pp.362-367.

Casado Marín, C., Puig-Junoy, J. and Puig-Peiró, R., 2009. El impacto de la demografía sobre el gasto sanitario futuro de las Comunidades Autónomas. Colección de documentos de trabajo 2009. Madrid: Fundación Pfizer.

Farrar, S., Yi, D., Sutton, M., Chalkley, M., Sussex, J. and Scott, A., 2009. Has payment by results affected the way that English hospitals provide care? Difference-in-differences analysis. British Medical Journal, 339, b3047.

Shah, K.K., 2009. Severity of illness and priority setting in healthcare: A review of the literature. Health Policy, 93(2-3), pp.77-84.

Sussex, J., 2009. Paying for better outcomes – the English way. Journal of Health Services Research and Policy, 14(3), pp.131-132.

Sussex, J. and Farrar, S., 2009. Activity based funding for National Health Service hospitals in England: Managers'experience and expectations. European Journal of Health Economics, 10(2), pp.197-206.

Towse, A., 2009. Should NICE’s threshold range for cost per QALY be raised? Yes. British Medical Journal, 338, b181.


Casado Marín, C., Puig-Peiró, R. and Massons Capdevila, S., 2008. La Despesa pública en cures de llarga durada a Catalunya: Situación actual i perspectives de futur. Barcelona: Departament d'Economia i Finances, Generalitat de Catalunya. Collecció: Monografies (9).


Garrison, L.P., Towse, A., and Bresnahan, B., 2007. Assessing a structured, quantitative health outcomes approach to drug risk-benefit analysis. Health Affairs, 26(3), pp.684-695.

Mason, A. and Towse, A. eds. (2007) The ideas and influence of Alan Williams. Be reasonable - do it my way! New York: Oxford Radcliffe Publishing.

Mestre-Ferrandiz, J., 2007a. El mercado de medicamentos genéricos: Regulación vs. competencia. ¿Qué podemos aprender de la experiencia internacional? Spanish Journal of Health Economics, 6(1), pp.33-36.

Mestre-Ferrandiz, J., 2007b. Use of health technology assessments in selected countries. What are the key trends and issues going forward? Spanish Journal of Health Economics, 6(4), pp.32-35.

Wilson, E., Sussex, J., Macleod, C. and Fordham, R., 2007. Prioritizing health technologies in a primary care trust. Journal of Health Services Research and Policy, 12(2), pp.80-85.


Buckingham, K. and Devlin, N., 2006. A theoretical framework for TTO valuations of health. Health Economics, 5(10), pp.1149-1154.

Drummond, M., Mason, A. and Towse, A., 2006. The desirability and feasibility of economic studies post-launch. European Journal of Health Economics, 1(7), pp.5-6.

Garau, M. and Mestre-Ferrandiz, J., eds. 2006. European medicines pricing and reimbursement. London: Radcliffe Publishing.

Mestre-Ferrandiz, J., 2006a. ¿Es el Pharmaceutical Price Regulation Scheme (PPRS) un mecanismo adecuado para regular el mercado farmacéutico británico? Spanish Journal of Health Economics, 5(1), pp.18-21.

Mestre-Ferrandiz, J., 2006b. Un paseo por los sistemas de precio y reembolso de medicamentos en Europa: Algunas tendencias. Spanish Journal of Health Economics, 5(3), pp.160-63.


Barbieri, M., Drummond, M., Willke, R., Chancellor, J., Jolain, B. and Towse, A., 2005. Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: Lessons for inferring generalizability. Value in Health, 8(1), pp.10-23.

Burge, P., Devlin, N., Appleby, J., Rohr, C. and Grant, J., 2005. Do patients prefer quicker treatment? A discrete choice analysis of patients' stated preferences in the London Patient Choice Project. Journal of Applied Health Economics and Health Policy, 3(4), pp.183-194.

Cooke, J., Mason, A., Drummond, M. and Towse, A., 2005. Medication management in English National Health Service hospitals. American Journal of Health-System Pharmacy, 62(2), pp.189-195.

Danzon, P. and Towse, A., 2005. Theory and implementation of differential pricing for pharmaceuticals. In Maskus, K. and Reichman, J. eds. International public goods and transfer of technology under a globalised intellectual property regime. New York: Cambridge University Press.

Dawson, D., Drummond, M., and Towse, A., 2005).European integration and the economics of health care. In Smith, P., Ginnelly, L. and Sculpher, M. eds. Health policy and economics: Opportunities and challenges. Maidenhead UK: Open University Press. pp.248-271.

Mason, A., Drummond, M., Hunter, J., Towse, A. and Cooke, J., 2005. Prescribing incentive schemes. Applied Health Economics and Health Policy, 4(2), pp.111-117.

Miners, A.H., Garau, M., Fidan, D. and Fischer, A.J., 2005. Comparing estimates of cost effectiveness submitted to the National Institute for Clinical Excellence (NICE) by different organisations: Retrospective study. British Medical Journal, 330, pp.65-69.

Sussex, J. and Sosa-Rubi, S., 2005. Paying for capital. In Preker, A.S. and Langenbrunner, J.C. eds. Spending wisely: Buying health services for the poor. Washington, DC: The World Bank.

Towse, A., 2005. Commentary on basic research funds to discover important new drugs: Who contributes how much? In Monitoring financial flows for health research: Behind the global numbers. Geneva: Global Forum for Health Research.

Towse, A. and Kettler, H., 2005a. Advance price or purchase commitments to create markets for treatments for diseases of poverty: Lessons from three policies. Bulletin of the World Health Organization, 83(4), pp.301-307.

Towse, A. and Kettler, H., 2005b. A review of IP and non-IP incentives for R&D for diseases of poverty. What type of innovation is required and how can we incentivise the private sector to deliver it? Final Report to the World Health Organization Commission on Intellectual Property Rights, Innovation, and Public Health.

Devlin, N., Hansen, P., Herbison, P. and Macran, S., 2005. A 'new and improved'EQ-5D valuation questionnaire? The European Journal of Health Economics, 50, pp.73-82.


Fenn, P., Gray, A., Rickman, N. and Towse, A., 2004. Making amends for negligence. British Medical Journal, 328, pp.417-418.

Mason, A., Drummond, M., Towse, A. and Cooke, J., 2004. Influencing prescribing in English primary care: The views of primary care organisations. Journal of Health Services Research and Policy, 9(3), pp.153-158.

Ossa, D. and Towse, A., 2004. Genetic screening, health care and the insurance industry: Should genetic information be made available to insurers? European Journal of Health Economics, 5(2), pp.116-121.

Devlin, N., Hansen, P. and Selai, C., 2004. Understanding health state valuations: a qualitative analysis of respondents' comments. Quality of Life Research, 13, p.1265.

Devlin, N. and Parkin, D., 2004. Does NICE have a cost effectiveness threshold and what other factors influence its decisions? A binary choice analysis- Health Economics, 13(5), pp.437-452.

Sussex, J., 2004. Principles of capital financing and capital charging in health care systems. World Bank Health Nutrition and Population Discussion Paper. Washington, DC: The World Bank.

Towse, A., Mestre-Ferrandiz, J. and Renowden, O., 2004. Estimates of the medium-term financial resource needs for development of pharmaceuticals to combat ‘neglected diseases’. In Combating diseases associated with poverty: Financing strategies for product development and the potential role of public-private partnerships. Geneva: Global Forum for Health Research.

Perkins, MRV., Devlin, N. and Hansen, P., 2004. The validity and reliability of EQ-5D health state valuations in a survey of Māori. Quality of Life Research, 13, pp.271-274.

Towse, A., Mills, A. and Tangcharoensathien, V., 2004. Learning from Thailand’s health reforms. British Medical Journal, 328, pp.103-105


Danzon, P. and Towse, A., 2003. Differential pricing for pharmaceuticals: Reconciling access, R&D and patents. Journal of Health Care Financing and Economics, 3(3), pp.183-205.

Devlin, N., Hansen, P., Kind, P. and Williams, A., 2003. Logical inconsistencies in survey respondents’ health state valuations – a methodological challenge for estimating social tariffs. Health Economics, 12(7), pp.529-544.

Garrison, L. and Towse, A., 2003. The drug budget silo mentality in Europe: An overview. Value in Health, 6(S1), pp.S1-S9.

Mestre-Ferrandiz, J., 2003a. Reference prices and generic medicines: What can we expect? Journal of Generic Medicines, 1(1), pp.31-38.

Mestre-Ferrandiz, J., 2003b. Reference prices: The Spanish way. Investigaciones Económicas, 27(1), pp.125-149.

Mestre-Ferrandiz, J., 2003c. Trends in international pricing and reimbursement. In: The pharmaceutical pricing compendium. London: Urch Publishing.

Sussex, J., 2003a. Private provision of publicly funded hospital care: The story so far. In: Private hospital healthcare Europe. London: Campden Publishing Ltd.

Sussex, J., 2003b. Public-private partnerships in hospital development: Lessons from the UK’s 'Private Finance Initiative'. Research in Healthcare Financial Management, 8(1), pp.59-76.

Towse, A., 2003. The efficient use of pharmaceuticals: Does Europe have any lessons for a Medicare drug benefit? Health Affairs, 22(3), pp.42-45.


Danzon, P. and Towse, A., 2002. The economics of gene therapy and of pharmacogenetics. Value in Health, 5(1), pp.5-13.

Goddard, M. and Sussex, J., 2002. Long-term aims and short-term realities: The impact of the NHS/private sector concordat. Applied Health Economics and Health Policy, 1(4), pp.165-169.

Sussex, J., 2002. The NHS and PFI. In: Neville, T. ed. PFI: Practical perspectives. London: Association of Chartered Certified Accountants.

Towse, A. and Pritchard, C., 2002. National Institute for Clinical Excellence (NICE): Is economic appraisal working? Pharmacoeconomics, 20(Suppl. 3), pp.95-105.


Danzon, P. and Towse, A., 2000. The genomic revolution: Is the real risk under-investment rather than bankrupt health care systems? Journal of Health Services Research and Policy, 5(4), pp.253-255.

Towse, A. and Sussex, J., 2000. Getting UK health care expenditure up to the European Union mean. What does that mean? British Medical Journal, 320, pp.640-642.

1999 and earlier

Mason, A., Drummond, M. and Towse, A., 1999a. Is disease management relevant in Europe: Some evidence from the United Kingdom. Health Policy, 48(1), pp.69-77.

Mason, A., Drummond, M. and Towse, A., 1999b. Joint disease management ventures in the UK. Journal of Integrated Care, 3(2), pp.71-78.

Mestre-Ferrandiz, J., 1999. Relación entre un sistema de precios de referencia y medicamentos genéricos. Hacienda Pública Española, 150(3), pp.173-180.

Mestre-Ferrandiz, J., 1999. The impact of generic goods in the pharmaceutical industry. Health Economics, 8(7), pp.599-612.

Pritchard, C. and Towse, A., 1999. Methodologies used to evaluate and measure the economic outcomes of drug treatments. In: Sale, K. ed. Pharmacoeconomics and outcome assessment: A global issue. Hasslemere: Euromed Communications. pp.33-52.

Towse, A. (1998) The pros and cons of a single ‘Euro-price’ for drugs. PharmacoEconomics, 13(3), 271-276.

Towse, A. and Teeling Smith, G., 1994. The economics of healthcare. In: Griffin, J.P., O’Grady, J. and Wells, F.O. eds. Textbook of pharmaceutical medicine. Belfast: Queens University of Belfast.